MoonLake Immunotherapeutics - 8-K Filing
MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement and Capacity Agreement with Vetter Pharma International GmbH on May 22, 2026. The agreements involve manufacturing application systems pre-filled with active pharmaceutical ingredients for the company's products, including sonelokimab. These contracts build upon an existing master development agreement from October 27, 2021. (Items: 1.01 Entry into a Material Definitive Agreement On May 22, 2026, MoonLake Immunotherapeutics (the “Company”) entered into a Master Commercial Supp)
Tickers: $MLTX